Cargando…

Rituximab in the treatment of non-Hodgkin’s lymphoma

Besides traditional cytostatic drugs the introduction of monoclonal antibodies has substantially influenced current treatment concepts of non-Hodgkin’s lymphoma (NHL). Rituximab, a monoclonal anti-CD20 chimeric antibody, now has been widely evaluated in the various B-cell lymphatic neoplasms. Large...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauptrock, Beate, Hess, Georg
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727901/
https://www.ncbi.nlm.nih.gov/pubmed/19707443
_version_ 1782170706835931136
author Hauptrock, Beate
Hess, Georg
author_facet Hauptrock, Beate
Hess, Georg
author_sort Hauptrock, Beate
collection PubMed
description Besides traditional cytostatic drugs the introduction of monoclonal antibodies has substantially influenced current treatment concepts of non-Hodgkin’s lymphoma (NHL). Rituximab, a monoclonal anti-CD20 chimeric antibody, now has been widely evaluated in the various B-cell lymphatic neoplasms. Large phase III studies helped to prove the value of this drug in follicular lymphoma as part of induction or relapse treatment as well as maintenance treatment. The addition of rituximab to the well established CHOP regimens has increased achievable cure rates in diffuse large cell lymphoma, and this combination is now accepted worldwide as standard of care. Although conflicting results are available, rituximab is widely used for the treatment of mantle cell lymphoma. For the less frequent lymphoma entities phase 2 studies show a considerable efficiency for most of these B-NHL variants. Current research focuses on combined chemoimmunotherapy approaches, optimization of dosing regimens, and combination with novel agents.
format Text
id pubmed-2727901
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-27279012009-08-25 Rituximab in the treatment of non-Hodgkin’s lymphoma Hauptrock, Beate Hess, Georg Biologics Review Besides traditional cytostatic drugs the introduction of monoclonal antibodies has substantially influenced current treatment concepts of non-Hodgkin’s lymphoma (NHL). Rituximab, a monoclonal anti-CD20 chimeric antibody, now has been widely evaluated in the various B-cell lymphatic neoplasms. Large phase III studies helped to prove the value of this drug in follicular lymphoma as part of induction or relapse treatment as well as maintenance treatment. The addition of rituximab to the well established CHOP regimens has increased achievable cure rates in diffuse large cell lymphoma, and this combination is now accepted worldwide as standard of care. Although conflicting results are available, rituximab is widely used for the treatment of mantle cell lymphoma. For the less frequent lymphoma entities phase 2 studies show a considerable efficiency for most of these B-NHL variants. Current research focuses on combined chemoimmunotherapy approaches, optimization of dosing regimens, and combination with novel agents. Dove Medical Press 2008-12 2008-12 /pmc/articles/PMC2727901/ /pubmed/19707443 Text en © 2008 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Hauptrock, Beate
Hess, Georg
Rituximab in the treatment of non-Hodgkin’s lymphoma
title Rituximab in the treatment of non-Hodgkin’s lymphoma
title_full Rituximab in the treatment of non-Hodgkin’s lymphoma
title_fullStr Rituximab in the treatment of non-Hodgkin’s lymphoma
title_full_unstemmed Rituximab in the treatment of non-Hodgkin’s lymphoma
title_short Rituximab in the treatment of non-Hodgkin’s lymphoma
title_sort rituximab in the treatment of non-hodgkin’s lymphoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727901/
https://www.ncbi.nlm.nih.gov/pubmed/19707443
work_keys_str_mv AT hauptrockbeate rituximabinthetreatmentofnonhodgkinslymphoma
AT hessgeorg rituximabinthetreatmentofnonhodgkinslymphoma